1. Home
  2. FEMY vs KTTA Comparison

FEMY vs KTTA Comparison

Compare FEMY & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FEMY

Femasys Inc.

HOLD

Current Price

$2.59

Market Cap

22.4M

Sector

Health Care

ML Signal

HOLD

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.51

Market Cap

18.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEMY
KTTA
Founded
2004
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.4M
18.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
FEMY
KTTA
Price
$2.59
$0.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$5.50
$3.00
AVG Volume (30 Days)
173.5K
214.9K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
44.71
77.07
EPS
N/A
N/A
Revenue
$2,293,313.00
$486,559.00
Revenue This Year
$105.16
N/A
Revenue Next Year
$200.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40.77
3130.37
52 Week Low
$0.29
$0.28
52 Week High
$6.29
$2.06

Technical Indicators

Market Signals
Indicator
FEMY
KTTA
Relative Strength Index (RSI) 42.01 47.80
Support Level $0.41 $0.48
Resistance Level $3.33 $0.52
Average True Range (ATR) 0.23 0.04
MACD -0.04 -0.01
Stochastic Oscillator 10.10 34.21

Price Performance

Historical Comparison
FEMY
KTTA

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Share on Social Networks: